Floatz Rating
C38/100
Confidence
Indicative
Sponsor
Tongji Hospital
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04561557CT.gov Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Autoimmune Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ct103a cells (this asset) | Tongji Hospital | Early P1 | C · 38 |
| Ursodeoxycholic Acid | West China Hospital | P4 | BB |
| Total Glucosides Of Paeony | West China Hospital | P4 | BB |
| Cyclophosphamide | The Children's Hospital of Zhejiang University School of Medicine | P2 | B |
| Cephalexin | Mayo Clinic | P4 | B |
| Cefadroxil Anhydrous | Mayo Clinic | P4 | B |
| Doxycycline | Mayo Clinic | P4 | B |
| Human Immunoglobulins | University of Cambridge | P3 | B |
| Nivestim | Johns Hopkins University | P2 | B |
+27 more in the Autoimmune Disease cohort
Other indications for ct103a cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Idiopathic Inflammatory Myopathy | — | Early P1 | C · 39 |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy | — | Early P1 | C · 39 |
| Autoimmune Encephalitis | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ct103a cells in Autoimmune Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ct103a-cells-autoimmune-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →